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ABSTRACT
Introduction: While overall survival for most common
cancers in Australia is improving, the rural–urban
differential has been widening, with significant excess
deaths due to lung, colorectal, breast and prostate
cancer in regional Australia. Internationally a major
focus on understanding variations in cancer outcomes
has been later presentation to healthcare and later
diagnosis. Approaches to reducing time to diagnosis of
symptomatic cancer include public symptom
awareness campaigns and interventions in primary care
to improve early cancer detection. This paper reports
the protocol of a factorial cluster-randomised trial of
community and general practice (GP) level
interventions to reduce the time to diagnosis of cancer
in rural Western Australia (WA).
Methods and analysis: The community intervention
is a symptom awareness campaign tailored for rural
Australians delivered through a community
engagement model. The GP intervention includes a
resource card with symptom risk assessment charts
and local referral pathways implemented through
multiple academic detailing visits and case studies.
Participants are eligible if recently diagnosed with
breast, colorectal, lung or prostate cancer who reside
in specific regions of rural WA with a planned sample
size of 1350. The primary outcome is the Total
Diagnostic Interval, defined as the duration from first
symptom (or date of cancer screening test) to cancer
diagnosis. Secondary outcomes include cancer stage,
healthcare utilisation, disease-free status, survival at 2
and 5 years and cost-effectiveness.
Ethics and dissemination: Ethics approval has
been granted by the University of Western Australia
and from all relevant hospital recruitment sites in WA.
Results: Results of this trial will be reported in peer-
reviewed publications and in conference
presentations.
Trial registration number: Australian New Zealand
Clinical Trials Registry (ANZCTR).
ACTRN12610000872033.
BACKGROUND
Rural Australians are more likely to die
within 5 years of a cancer diagnosis than
people from metropolitan areas.1 While
overall survival for most common cancers in
Australia is improving, the rural–urban differ-
ential has been widening, with significant
excess deaths due to lung, colorectal, breast
and prostate cancer in regional Australia.2
Similar disparities in cancer outcomes across
certain patient groups have been described
worldwide.3 As part of the International
Strengths and limitations of this study
▪ This is the first large scale randomised controlled
trial to test the implementation of cancer risk
tools based on the Hamilton CAPER studies. It is
also novel in that it will measure the effect of
separate and combined community and general
practice interventions on time to cancer
diagnosis.
▪ Longer term follow-up will assess the impact on
survival.
▪ The community control area was matched as
closely as possible within the constraints of the
population distribution in different regions of
Western Australia.
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Cancer Benchmarking Partnership, a major focus on
understanding variations in cancer outcomes has been
later presentation to healthcare and later diagnosis.4
Previous studies have shown that patients living in
rural Australia are less likely to receive curative or recon-
structive surgery, radiotherapy or anticancer drug treat-
ment.5–8 Policy initiatives have focused, therefore, on
reducing disparities in access to treatment.9 Access to
treatment is an important determinant of outcome, but
later presentation and stage at diagnosis have also been
observed in rural patients with cancer.10 11 International
research suggests that the time taken to appraise symp-
toms and seek help (so-called ‘patient delay’) and man-
agement in primary care are also key determinants of
cancer outcomes.12 Time to diagnosis is associated with
poorer survival for several common cancers.13 14
One of the approaches to reducing later presentation
to healthcare has been community symptom awareness
campaigns. These have formed a major component of
the UK National Awareness and Early Diagnosis
Initiative (NAEDI) as part of the policy to improve
cancer outcomes.15 A systematic review of cancer
symptom awareness campaigns published in 2009 found
insufficient evidence about their effect on presentation
to healthcare.16 Since then further studies have begun
to show potential effects on presentation and cancer
diagnoses.17
A second approach has aimed at improving early recog-
nition of patients in primary care with symptoms suggest-
ive of cancer. A major challenge for general practitioners
(GPs) is that the symptoms of many cancers are common
in the community and overlap with prevalent benign con-
ditions. GPs need to assess the risk, or diagnostic prob-
ability, of an underlying cancer and determine whether
further investigation is justified. Until recently, there was
little epidemiological evidence demonstrating how well
symptoms predict risk of an underlying cancer from
primary care populations.18 Analysis of data in case–
control studies using large UK general practice databases,
notably the CAPER (Cancer Prediction in Exeter)
studies19–22 and QCancer research,23 24 has led to signifi-
cant advances in our understanding of the epidemiology
of cancer symptoms in primary care.
The CAPER studies have quantified the risk of individ-
ual and paired symptoms, signs and primary care investi-
gations for a number of cancers including colorectal,
lung and prostate. These have been evaluated as risk
assessment tools (RATs) in paper versions25 and are cur-
rently undergoing evaluation as computerised decision
support tools embedded in the electronic medical
records of English general practices.26 Various interven-
tions including audit and feedback, educational visits,
guidelines and decision support have been tested in
general practice to improve cancer diagnosis.27 None of
the 22 trials included in a systematic review of interven-
tions to support cancer diagnosis in primary care exam-
ined effects on diagnostic delay, although audit and
feedback was shown to improve clinical management.28
Conducting research in the field of ‘diagnostic delay’
in cancer has many methodological challenges. The
Aarhus statement discusses these and provides consensus
guidelines on appropriate definitions and the conduct
and reporting of such research.29 One recommendation
is the application of theoretical models such as The
Model of Pathways to Treatment30 31 (figure 1). This
model proposes four key intervals:
1. The Appraisal Interval: The nature of a person’s
symptoms is one of the most important factors deter-
mining the duration of the Appraisal Interval.
Misattribution of symptoms either to a previous
benign or concurrent condition or non-recognition
of the seriousness of symptoms contribute to longer
Appraisal Intervals.
2. The Help-Seeking Interval: Various factors may con-
tribute to this interval including patient factors such
as competing events (eg, holidays), and emotional
ones such as fear. This includes fear of the consult-
ation and examination, or of the diagnosis and treat-
ment. Access to primary care and sanctioning
help-seeking by family or friends, so that patients do
not perceive themselves as wasting the doctor’s time,
are also important factors.32
3. The Diagnostic Interval: Depending on the health-
care setting this may involve a series of healthcare
visits, referrals and investigations and often represents
a complex process. System factors including the role
of primary care as a gatekeeper and access to investi-
gations and specialist care are key factors determin-
ing this interval.
4. The Pre-Treatment Interval: The time from formal
cancer diagnosis to initiation of treatment is also
strongly influenced by several healthcare system
factors such as access to staging investigations and
specialised treatments.
Our research on rural cancer outcomes is applying
the well-established Medical Research Council (MRC)
methodological framework for the design and evaluation
of complex interventions.33 34 Our initial exploratory
mixed-methods study aimed to explore the context of
rural cancer diagnosis in WA and inform the develop-
ment of our complex intervention. In summary,
in-depth interviews with 66 people recently diagnosed
with breast, lung, prostate or colorectal cancer from
regional WA found longer duration of symptom
appraisal for colorectal cancer compared with other
cancers. Participants defined core characteristics of rural
Australians as optimism, stoicism and machismo. These
features, as well as poorer access to healthcare, contribu-
ted to later presentation of cancer.18 In addition, there
were significant overall differences between cancers in
terms of time from presentation in general practice to
referral, from GP referral to specialist appointment, and
from specialist appointment to cancer diagnosis. These
differences were due to the nature of presenting symp-
toms, access to diagnostic tests and multiple visits to spe-
cialists. Breast cancer was diagnosed more quickly
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because its symptoms are more specific and well recog-
nised by the community, and due to better access to
diagnostic tests and specialist one-stop clinics.35
These findings contributed to the development of the
interventions and design of the Improving Rural Cancer
Outcomes (IRCO) Trial: a factorial cluster-randomised
controlled trial of community-based and general practice-
based interventions which aims to reduce the time to
diagnosis in rural patients presenting with prostate,
breast, colorectal or lung cancer in Western Australia.
METHODS AND TRIAL DESIGN
Design and setting
This 2×2 factorial cluster randomised controlled trial is
set in Western Australia, the largest Australian state geo-
graphically, with a population of 2.29 million (approxi-
mately 10% of the Australian population). Two-thirds of
the WA population live in metropolitan Perth and the
remainder are widely geographically dispersed. Two
Trial Areas were matched for population size, demo-
graphics including age and Aboriginality, and similar
cancer incidence, based on the most recent available
data (from 2006) when the trial was planned (figure 2
presents more recent data on population size from
2010). Trial Area A comprises the Wheatbelt (155
256km²), Goldfields (770 488 km²) and Great Southern
(39 007 km²) regions, and Trial Area B includes the
Peel/South West (29 646 km²) and MidWest (470 000
km²) regions.36
Randomisation
Trial Area A has been allocated to receive the commu-
nity symptom awareness campaign intervention and
Trial Area B acts as the community campaign control
region. In both Trial Areas general practices have been
randomised to receive the education intervention or
Figure 1 Model of pathways to treatment.
Figure 2 Map of Western Australia depicting the regional
boundaries of Trial Area A, receiving the community
intervention, and Trial Area B, acting as the community
control.
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control, stratified by practice size (≤1 GP; 2 to 4 GPs;
5+ GPs). GPs who worked at more than one practice
have been identified, and their practices have been
treated as one practice for the purpose of randomisation
to avoid contamination (figure 3).
Practices have been randomly assigned to intervention
or control arm using a cluster version of Zelen’s method
of postrandomised consent: intervention practices have
been invited to receive the educational package while
control practices receive no information about the
trial.37 This enables non-intervention practices to act as
true controls by minimising the Hawthorne effect in a
situation where placebo and double blind experimental
conditions are impossible to achieve. The Hawthorne
effect occurs when the researchers’ procedures and
communications act as interventions in themselves that
change behaviours, such as if the control cluster were to
adopt the practices or policies promoted to the interven-
tion cluster. This would destroy the trial’s ability to iden-
tify a benefit of the intervention, if one exists.
Furthermore, it allows a pragmatic delivery of the inter-
vention and measure of its uptake in routine practice.
Intervention practices which decline the invitation to
receive the educational package will be analysed on an
intention-to-treat basis. Randomisation has been per-
formed by the trial statistician. As the number of
working GPs in a given practice varies, the randomisa-
tion has taken into account practice size. Each practice
has been categorised into: one GP in the practice,
2–4 GPs or five or more GPs. A random sample propor-
tional to the size of the practice has been used employ-
ing ‘samplepps’ macro in Stata.
Patient recruitment and inclusion criteria
From 1 March 2012, 4 months after the interventions
started, all patients meeting the following criteria are
being invited to contribute their data for the trial:
▸ Adults aged over 18 years;
▸ Diagnosed with breast, lung, colorectal or prostate
cancer between 1 January 2012 and the recruitment
end date of 31 March 2014; and
▸ Resident of Trial Areas A or B at the time of
diagnosis.
Recruitment strategy
Eligible participants are identified via:
1. The WA Cancer Registry (WACR): A letter and par-
ticipant information sheet is mailed from the WACR
directly to newly diagnosed patients with cancer.
After 3 weeks non responders are followed up by the
research team via phone or mail.
2. Cancer Council Western Australia’s (CCWA) residen-
tial lodges: We approach eligible patients while
staying at CCWA charitable accommodation during
their cancer treatment in Perth. A large proportion
of rural patients with cancer, especially those receiv-
ing radiotherapy or chemotherapy, reside in one of
the lodges for several weeks during their treatment.
Eligible patients receive the same participant infor-
mation sheet as part of their Lodge Welcome Pack by
the lodge receptionists and are followed up by the
research team.
Participants are invited to sign a consent form, which
includes agreement to access their medical records, and
return it with their completed SYMPTOM questionnaire.
Figure 3 The 2×2 factorial
cluster randomised controlled trial
design.37
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Study interventions
The Trial includes interventions at two levels: a commu-
nity symptom awareness campaign (‘the community
intervention’); and a GP educational package incorpor-
ating symptom risk assessment charts and referral
guidance which is implemented through multiple aca-
demic detailing visits and case studies (‘the GP interven-
tion’). Both interventions are being delivered between
1 November 2011 and 31 December 2013.
The community intervention
We modified existing resources developed for The
Cancer Research UK ‘Spot Cancer Early’ and the UK
National Health Service ‘3 week cough’ campaigns to
incorporate the findings of our exploratory mixed-
methods study,18 35 and to make them relevant to a rural
Australian community.
Materials have been further modified following three
community forums held in the major towns of the cam-
paign target regions. Feedback was obtained about the
campaign logo, design, choice of images, locally accept-
able language, and contact details. The campaign is
named the Find Cancer Early campaign and the materi-
als explicitly use the Cancer Council WA branding, recog-
nising the strong community support and credibility of
this organisation. Community members wanted the cam-
paign to focus on the positives associated with early detec-
tion and the use of simple, non-medical terms when
describing symptoms. A campaign message development
meeting was then held between the project team, social
marketing experts and health professionals to develop a
framework for the campaign and message hierarchy.
The target of the campaign is men and women over
the age of 40; it aims to raise awareness of the symptoms
of bowel, lung, prostate and breast cancer and to help
people overcome the barriers to seeking medical help.
The primary campaign item is a plain-language
symptom checklist (figure 4). Other materials include:
newspaper adverts based on campaign materials; radio
adverts for each of the four cancers; tumour-specific
postcards featuring regional images and quotations
about relevant symptoms (figure 4); generic postcards
providing strategies to overcome barriers to seeking help
(figure 4); a DVD outlining tumour specific symptoms
featuring health professionals and regional community
members; an Indigenous version of the symptom check-
list; a website; and posters and banners.
Five project officers, with a combined full time equiva-
lent of 3, are delivering the campaign across the three
regions of WA in Trial Area A. They use a community
engagement approach building partnerships to deliver
and disseminate the campaign messages with presenta-
tions, displays and campaign resource distribution. Paid
advertising and articles in regional newspapers and radio
supplement this dissemination strategy. Television is not
being used to avoid contamination in the control area.
Figure 4 Examples of Find Cancer Early resources—General Symptom Checklist, Prostate postcard and Tell your doctor
postcard.
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The GP intervention
A GP education resource card, ‘The Rural Cancer
Initiative: a Guide for General Practitioners’, has been
developed with input from rural GPs and health profes-
sional advisors. The novel aspect of this intervention is
the implementation of the CAPER risk assessment charts
for colorectal,21 lung20 and prostate22 cancer. The
resource card contains the clinical implications of these
risk charts including diagnostic assessment. In addition
the resource card summarises the National Breast and
Ovarian Cancer Centre guidelines for investigating new
breast symptoms38 and local referral guidelines and hos-
pital contacts, including recommendations about access
to cancer multidisciplinary teams.39
The GP resource card is being implemented through a
series of four academic detailing practice visits, supple-
mented by a series of question-and-answer case studies for
completion between visits designed to reinforce key mes-
sages.40 The practice visits present specific components of
the resource card and facilitate discussion within the prac-
tice around recently diagnosed patients with cancer. GPs
are eligible for Royal Australian College of General
Practitioners and Australian College of Rural and Remote
Medicine professional development points on completion
of the case studies and attendance at practice visits.
OUTCOMES AND MEASURES
Primary outcome
The primary outcome is the Total Diagnostic Interval
(TDI), defined as the time from first symptom to diagno-
sis. We will report our time intervals according to the prin-
ciples outlined in the ‘Aarhus Statement’ on the conduct
and reporting of research on cancer diagnosis,29 and will
use the Model of Pathways to Treatment as our theoretical
framework.30 31 The date of first symptom is defined as
‘the time-point when first bodily change(s) and/or
symptom(s) is noticed’. For screen-detected cases we use
the date of attendance for the screening test as the initial
date in the patient pathway. Date of diagnosis is based on
pathological diagnosis as reported to the WA Cancer
Registry. We will divide the Total Diagnostic Interval
further to include time from first presentation in general
practice to referral (GP Interval), date of referral to first
attendance at specialist (Specialist Access Interval), and
time from first attendance at the specialist to date of diag-
nosis (Specialist Interval).41 The GP Interval includes the
time taken to order and respond to investigations available
directly in primary care. For patient-reported dates we will
apply published mid-point rules to estimate the actual date
where uncertainty exists.12 Where necessary, a clinical con-
sensus group will review the data to confirm the date of
first symptom and first presentation to healthcare.
Measurement tools
The following instruments will be used to obtain infor-
mation about symptoms and key dates to calculate the
Total Diagnostic Interval:
1. SYMPTOM Questionnaire: This self-administered
questionnaire was developed from the C-SIM42
measure and has been applied in the UK SYMPTOM
study.43 It includes items specific to each tumour site
to capture details of symptoms, their date of onset
and time taken to seek help.
2. GP record audit tool: This tumour-specific proforma
is mailed to the participant’s GP to obtain key infor-
mation on: the date, type and duration of presenting
symptoms within the last 12 months, referral informa-
tion including referral date, and date of first appoint-
ment with specialist.
Date of cancer diagnosis is obtained from the WA
Cancer Registry.
Secondary outcomes
Process measures of intervention delivery
A. Campaign Dose: Process evaluation is conducted in
each intervention town to collect data on the
amount of media exposure achieved, number of
campaign resources distributed, number of partner-
ships established, and number of presentations,
events and other activities carried out by campaign
staff to promote the campaign messages. Information
is collected via monthly reports by the campaign
project officers.
B. Media Exposure: Media exposure is measured by
number and square centimetre coverage of paid
press advertisements and unpaid press articles. The
value of unpaid media is estimated by calculating the
square centimetre space and calculating the cost to
purchase that space.
C. GP Monitoring: The campaign project officers document
number of visits conducted, GP attendance at each visit,
and number of case studies completed.
D. Costs of intervention delivery: Cost data of delivering
the interventions are being collected prospectively
(see Health Economic Evaluation below).
Impact measures of intervention
Campaign awareness is being measured at 18 months
into the campaign intervention by a computer-assisted
telephone interview survey. The survey is being con-
ducted on a random sample of adults above 40 years old
from the campaign regions and control regions stratified
by sex and age, and regions within Trial Area
A. Questions measure exposure to the campaign, includ-
ing unprompted and prompted awareness of campaign
elements (ie, radio, print and campaign brand and
logos). Respondents reporting any exposure to the cam-
paign are asked additional questions about comprehen-
sion and perceived effectiveness.
Measures of clinical outcomes
We will use the WA data sets44 to provide linked hospital
morbidity and administrative, cancer diagnostic and
mortality data in order to examine trends across time on
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clinical outcomes at the level of the community and
individual. We will obtain these data in three tranches:
A. Cohort of patients diagnosed in 2002–2010 to
provide a baseline understanding of the patterns of
care and survival;
B. Cohort of patients diagnosed in 2011–2013 with all
linked data after at least 2 years of follow-up to evalu-
ate short-term clinical effects of the interventions on
cancer stage, healthcare utilisation and disease free
status;
C. Cohort of patients diagnosed in 2011–2013 with all
linked data after at least 5 years of follow-up to evalu-
ate medium-term clinical effects and survival.
Analysis
The cluster randomised design provides protection
against contamination across trial groups when trial
patients are managed within the same setting.45 The
primary analysis will compare the Total Diagnostic
Intervals and its subcomponents between trial groups.
Simple analyses such as t tests or more complex regres-
sion analyses will be undertaken. Time data are invari-
ably skewed and bounded by the absence of negative
times. We will apply a log transformation prior to con-
ducting general linear modelling to compare intervals
accounting for exposure to the community and GP
interventions within the model, accounting for cluster-
ing effects at the practice level. Where appropriate, com-
parisons of arithmetic or geometric means will be
performed. The aim of statistical modelling is to identify
the main factors that explain variation in the outcome
for example, patient and practice characteristics. The
primary aim is to adjust for the effect of covariates
before the effect of the intervention is tested as well as
‘intervention × phase’ interaction with premeasurements
and postmeasurements comparison. We will conduct a
series of sensitivity analyses to account for:
A. Symptoms reported with a duration of greater than
2 years which will be excluded from the primary
analysis.
B. Vague first symptoms such as fatigue and ‘feeling
different’.
Using cancer registry, hospital morbidity and death
data we will compare patterns of hospitalisation and
treatment, pseudostaging at diagnosis using established
methods where full staging data are not available,44 46–49
disease-free intervals and survival in people diagnosed
with breast, lung, colorectal or prostate cancer resident
in Trial Area A with those in Area B and those resident
elsewhere in non-metropolitan and metropolitan WA.
The comparisons will relate to patients diagnosed with
one of the four target cancers in the 6 years prior to the
interventions (2005–2010) and during the 2 years of
intervention (late 2011—late 2013). This will enable the
effects of the community-level intervention to be evalu-
ated as a spatial contrast. The same analyses will be con-
ducted after 5 years of follow-up. These analyses will
entail all patients with cancer in WA during the specific
time periods to assess the effects of the community inter-
vention. In addition, we will conduct analyses of all parti-
cipants who have given their consent to measure the
effects of exposure to the GP intervention and com-
bined effect of community and GP interventions on clin-
ical outcomes at 2 and 5 years.
All analyses will be conducted by trial statisticians
blinded to participant allocation.
Health economic evaluation
A health economic evaluation from a health system per-
spective will be undertaken to determine whether the
resources committed to the trial between the four inter-
vention arms represent a worthwhile investment in
terms of the measured outcomes. This will include a
cost-analysis of each intervention and a cost-effectiveness
analysis which will compare costs with related outcomes.
Cost components include: campaign intervention costs
(eg, staffing, travel, campaign resources, media, events,
in-kind support); GP intervention costs (eg, staffing,
travel, education programme, resources); additional staff
costs; non-intended costs of non-cancer diagnoses (hos-
pital utilisation); in-kind personnel contributions from
project partners. Resource units and cost per unit will
be applied to calculate total cost.
Outcome data will be matched to cost data. In the first
instance, cost per change in TDI will be calculated for
each of the four arms of the trial. Longer term cost-
effectiveness will also be calculated to estimate net cost
per life year gained for each intervention. The TDI will
provide a surrogate outcome for longer term outcomes
using modelling techniques. Once longer term follow-up
data are available, cost-effectiveness ratios will be
calculated.
Sample size
The original sample size required for 80% power and
α=0.05 to detect a halving of long-delay risk of 30% to
15% was 840 participants. This sample size calculation
accounted for the design effects from hierarchical corre-
lations and an intra-class correlation coefficient of 0.09
based on similar trial designs.50
Recruitment was planned to continue until 4 months
after completion of intervention delivery to allow inclu-
sion of a cohort of newly diagnosed patients with cancer
who were exposed to the interventions (ie, 31 March
2014). We have achieved approximately a 50% accrual
rate into the trial which was much higher than our ori-
ginal estimates. Our final estimated recruitment is 1359
participants. Based on the distributions of TDIs from
our previous research, 18 35 this sample will provide 80%
power to detect a 10% difference in TDI between inter-
vention groups for all four cancers combined, and a
20% difference in TDI for breast, colorectal and prostate
cancer separately, but not lung cancer as this would
require a sample of 2600 participants.
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